Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.51 |
| ▸ | DCUN1D1 | Q96GG9 | 10/20 | 0.50 |
| ▸ | UBE2M | P61081 | 8/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384698 | 0.91 | CDK8 (0.53) | CDK8EPHB4DCUN1D1UBE2MKIT | |
| SCHEMBL12302309 | 0.88 | KMT2A (0.50) | CDK8DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL2384350 | 0.85 | F10 (0.63) | MEN1KMT2AF10 | |
| SCHEMBL2386673 | 0.84 | CA12 (0.53) | CDK8EPHB4KITF10CA12 | |
| SCHEMBL2384090 | 0.82 | F10 (0.41) | CDK8F10TRPV1 | |
| SCHEMBL2384709 | 0.82 | TRPV1 (0.53) | EPHB4DCUN1D1UBE2MKITF10 | |
| SCHEMBL2383664 | 0.82 | TRPV1 (0.53) | EPHB4DCUN1D1UBE2MKITF10 | |
| SCHEMBL12250883 | 0.82 | TRPV1 (0.53) | EPHB4DCUN1D1UBE2MKITF10 | |
| SCHEMBL2384560 | 0.82 | TRPV1 (0.53) | EPHB4KITMEN1KMT2AF10 | |
| SCHEMBL2382825 | 0.81 | TRPV1 (0.51) | EPHB4DCUN1D1UBE2MKITF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | CDK8 600/4885EPHB4 410/4885DCUN1D1 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.